Murine monoclonal antibody therapy in two patients with chronic lymphocytic
leukemia
RO Dillman, DL Shawler, RE Sobol, HA Collins, JC Beauregard, SB Wormsley and I Royston
We infused the murine monoclonal antibody T101 into two patients with
advanced refractory chronic lymphocytic leukemia (CLL) after confirming its
reactivity with their CLL cells. One patient received doses of 1, 3, and 12
mg; the second patient received 10 mg. Antibody was delivered over 10--15
min. The major observations were: (1) T101 murine monoclonal antibody did
bind to cells with T65 surface antigen and saturated these cells in vivo;
(2) cells that bound T101 disappeared from the circulation by 2 hr after
treatment, as evidenced by a marked drop in lymphocyte counts; (3) T101
serotherapy resulted in some intravascular cell injury associated with
sequestration and probably destruction in the liver and lung; (4) free
serum T101 was demonstrable, but disappeared by 2--4 hr after infusion; (5)
rapid infusion of T101 did not induce significant modulation of T65; (6)
rapid infusion of greater than 10 mg of T101 was associated with
significant systemic reactions. Monoclonal antibodies may someday have an
application in leukemia therapy, but additional experimental trials are
clearly indicated.
Volume 59,
Issue 5,
pp. 1036-1045,
05/01/1982
Copyright © 1982 by The American Society of Hematology
